Introduction
Hepatocellular adenoma (HCA) is an uncommon benign tumour of the liver that occurs particularly in women during their reproductive years. The annual incidence rate of HCA is approximately 1-1.3 per 1,000,000 in women who have never used oral contraceptives (OC), compared to 30-40 per million in long-term users [1, 2] . Thus, most HCA's are associated with the use of OC [3] [4] [5] , an association which was first described in 1973 [3] . Other conditions associated with the presence of HCA have been described, including anabolic steroids, glycogen storage disease I and III and pregnancy [6] [7] [8] [9] [10] [11] [12] [13] . Most likely the association of HCA and pregnancy is due to the increased levels of steroid hormones [14, 15] . The presence of HCA can be complicated by hormone induced growth and subsequently, spontaneous haemorrhagic rupture that may threaten the life of both mother and child.
A growing or bleeding adenoma may present with persistent or acute severe pain localized in the upper right quadrant and in the epigastric region. Its presentation can be difficult to differentiate from more common aetiologies of abdominal pain in pregnancy, like preeclampsia, Haemolysis Elevated Liver enzymes and Low Platelets (HELLP) syndrome or non-obstetric pathology like appendicitis, gallbladder disease, biliary pancreatitis, or pulmonary embolism [16] . This differential diagnosis may lead to a diagnostic delay. Early detection of HCA and a correct management of these patients are highly important, since several manuscripts documented high maternal and fetal risks in case of a ruptured HCA during pregnancy with a reported maternal and fetal mortality rate of 44% and 38%, respectively [17] . In the last decennium, the introduction and widespread use of highly advanced image modalities have probably decreased the doctors' delay in the diagnosis of HCA and the associated maternal and fetal mortality risk might be reduced significantly. No ruptures associated with gestation were reported in tumours less than 6.5 cm in size [17] . In non pregnant women haemorrhage has been documented in a tumour of 4.5 cm in size but is most commonly seen in tumours greater than 10 cm [17] . The risk of rupture is highest during the third trimester, most likely due to the cumulating level of estrogens and an increase in hyperdynamic circulation combined with an increase in vascularity of the liver with growth of the adenoma [17] . In the postpartum period, the risk of bleeding seems to be high as well; this can be explained by the sudden withdrawal of estrogens after delivery that may cause a sudden massive regression of the tumour leading to haemorrhage [17] . Because of the unpredictable behaviour of HCA and high maternal and fetal mortality of a ruptured HCA during pregnancy women with a large HCA or a growing and hormone sensitive HCA are advised to avoid pregnancy by most experts (either incidental findings previous to a pregnancy or women who experienced complications of an adenoma during pregnancy) [2, 15] . In addition, pregnancy itself limits the diagnostic modalities and interventions may be associated with greater risks in case of large adenomas [17] .
At our centre, HCA's with a diameter of 5 cm or larger that do not show adequate regression after discontinuation of the use of OC are considered for invasive treatment before pregnancy [15] . We were able to study 12 patients from a prospectively acquired database who sustained HCA's of different sizes during a total number of 17 pregnancies.
Patients and methods
The Erasmus Medical Centre is a tertiary referral centre for focal liver lesions with an area of adherence of approximately 4 million people. From 2000 to 2009 all data of patients with HCA were recorded prospectively in a weekly multidisciplinary meeting attended by a radiologist, hepatologist, pathologist, and surgeon specialized in solid liver tumours. At the time of diagnosis every HCA patient was advised to discontinue the use of OC and to prevent pregnancy. If pregnancy would nevertheless occur, patients were strongly advised to contact our centre to evaluate growth of the tumour by the surgeon or hepatologist. Follow-up of the fetus was carried out by the gynaecologist on a regular basis. A gynaecologist was consulted only in those cases where a significant growth of the adenoma was observed and its management could influence pregnancy. The patients described (12 of 183 patients with HCA) were diagnosed by contrast enhanced CT or MR imaging between January 2000 and December 2009. Until 2008 Gadolinium was the contrast agent of choice for MR imaging. In some cases, Gadolinium was followed by Resovist contrast for increased diagnostic certainty. After 2008, MultiHance was the contrast agent of choice for MR imaging.
During their pregnancy they were closely monitored by means of repetitive ultrasound and/or MR imaging. The frequencies of the measurements had no fixed time schedule and depend on the size and changes in the characteristics of the lesion. Their files were reviewed to evaluate presentation and time of presentation, use of OC, size and growth before and during pregnancy and postpartum, complications and management during pregnancy, gestation time and way of delivery, maternal and fetal outcome, and complications and management after delivery.
Results
Nearly all women (11 of 12) were diagnosed with HCA prior to their pregnancy. In one patient, HCA was diagnosed during pregnancy (Table 1) . Eleven patients were using OC at the time of diagnosis, or had used OC in the past. In four patients there had been a regression of HCA's after discontinuation of OC. One patient became pregnant before it was possible to evaluate her hormone sensitivity for the HCA. Another two patients stopped OC before HCA was diagnosed. In one patient there was growth of the HCA two and a half years after discontinuation of OC. No regression or growth of the HCA was noticed in three patients. Ten patients presented in the first trimester of pregnancy for monitoring of the HCA (Table 2 ). In one patient with multiple HCA's (case No. 3) there was serious concern about the risk of rupture of these lesions. One year before pregnancy she presented with an acute sensation of upper right quadrant pain, based on an intracapsular haemorrhage of an HCA. She withdrew from medical attention during the first trimester of her first pregnancy, but presented at the gynaecologist at 33 weeks gestation because of diabetes gravidarum. Until then, the patient was under surveillance at her general practitioner. At 33 weeks gestation, MR imaging, after ultrasound was performed, revealed a significant growth of the largest lesion from 32 to 75 mm (Fig. 1) . Another lesion showed signs of haemorrhage that had been noticed 2 years ago. At that time the lesion was measured 60 mm. This lesion measured 40 mm during her 33 weeks of gestation. To exclude any further risks, it was decided to deliver the child by means of a Caesarean section at 36 weeks with close postpartum monitoring of the mother at the Intensive Care Unit for several days because of an increased risk of haemorrhage. Despite our advice to showed growth in association with pregnancy and regression of the tumour postpartum (Figs. 2 and  3 ). In one patient (case No. 9), who wanted to keep her pregnancy, the tumour was treated with radiofrequency ablation (RFA) during the first trimester of her second pregnancy. The HCA showed regression during her pregnancy from 43 Â 35 mm to 27 Â 19 mm. Maternal and fetal outcomes were excellent in all cases and none of the HCA's resulted in complications during pregnancy or after delivery.
Discussion
The diagnosis of HCA may severely impact the life of a young fertile woman, in particular because of the overall agreed advice to avoid pregnancy. Literature on the course of HCA during pregnancy and recommended management is scarce. Some authors advocate that women with HCA should not get pregnant [2, 15] . As to date we cannot identify precisely those at risk of complications. It is likely that only a small subgroup of patients may experience complications. We provide a small but unique series of women who were monitored meticulously during pregnancy. Most cases of HCA related to pregnancy described in the literature were presented during pregnancy or shortly postpartum. From the international literature between 1966 and 2003, Cobey et al. retrieved 26 cases of women presenting with HCA during pregnancy or early postpartum and proposed an algorithm for their diagnosis and management [17] . Presentation was acute and often dramatic with rupture of the adenoma in 16 women, and frequently with a delay in establishing the correct diagnosis, with high maternal and fetal mortality. An aggressive approach towards resection of HCA was advocated, especially for those greater than 5 cm, based upon the high maternal and fetal mortality (44% and 38%, respectively) for women presenting with HCA during pregnancy. Small adenomas were supposed to be managed by observation [17] . We have previously reported that more than half of the HCA's are discovered after the patient has sustained at least one pregnancy [18] . None of these patients have reported problems during their pregnancies. In the current small series, just one patient presented with a tumour growth of real concern and that demanded an invasive intervention during pregnancy. In addition, rupture or other complications of solitary or multiple HCA's did not occur during intensive follow-up.
Based on these data we believe that a plea for a less aggressive surgical approach towards HCA in pregnant women may be justified. Especially in small tumours (<5 cm) we propose close monitoring and we believe it can be safe to allow pregnancy. However, in some women in whom the growth of the HCA is substantial there is reason for concern. Some authors suggest a Caesarean section (C-section) for HCA given the tendency to rupture at term [17] . In our study three C-sections (two patients) were performed, without complications. In one case (No. 3) C-section was performed in consultation with the patient because of marked growth and an unknown risk of rupture of the HCA's. In the other patient (case No. 10) C-section was due to decelerations on the cardiotocography. All other patients had a normal delivery which was never complicated by the rupture of an HCA. Therefore, in our opinion, patients with HCA may deliver vaginally if there are no complicating factors, like perinatal problems.
Prognostic factors on rupture and malignant degeneration during pregnancy remain unknown until this moment. Women with HCA's must be informed about the possible risks before pregnancy. The literature on the management of HCA's during pregnancy is scarce due to the low incidence of HCA's in general [2, 15] , and the low number of HCA's detected during pregnancy in particular. Growth of HCA in pregnant women requires special considerations for contemplating and timing possible interventions.
In the case an intervention is indicated, surgical resection as well as a minimal invasive approach may be considered, especially in smaller lesions. An intervention is safest in the 2nd trimester [14] . RFA is a minimally invasive technique, which is widely used for the treatment of patients with primary and secondary malignant tumours especially when resection is not an option. RFA is believed to be a relatively safe procedure in experienced hands with low mortality and morbidity [19] [20] [21] [22] . In 2006, Fujita et al. reported a pregnant patient with a HCA that was treated by RFA during her 18th gestational week [23] . In our centre RFA is occasionally used as an alternative treatment in women with HCA. A disadvantage of RFA is that after ablation of the tumour there is no material for pathological analysis. When there is any doubt about the diagnosis, especially about the benign character of the tumour, the diagnosis should be confirmed first. If malignancy cannot be excluded, surgical resection is preferred. Selective arterial embolization can be used both as an elective treatment to reduce the size of the HCA as well as the initial emergency treatment in case of active bleeding of the HCA [24] [25] [26] . It is a minimal invasive and safe procedure compared to laparotomy and complications are rare. There are no large patient series, and especially in pregnant women with HCA there is little experience with the use of arterial embolization, although some authors suggest that it is a safe and effective treatment for HCA [27, 28] . Since the risk of radiation exposure [29, 30] to the fetus is increased, especially before 26 weeks of gestation, we feel that selective arterial embolization should only be used as an emergency treatment when RFA or surgery are not a favourable option, for instance for more centrally located tumours that are hardly accessible for RFA.
In conclusion, based on our small but unique prospective series we propose not to discourage all women with HCA's from pregnancy. We hypothesize that pregnancy may be allowed in case of a known HCA under certain conditions such as size and after discussing the risk-benefit ratio with the patient. Women should be aware of the potential risks as an intervention may still be indicated during pregnancy, especially if the lesion is accessible for limited surgical resection or a percutaneous RFA. Close monitoring by liver ultrasound every 6 weeks may offer adequate information for surveillance of the hepatic lesion. In women who have large tumours or who have experienced complications of HCA in previous pregnancies, a negative advice against pregnancy is justified because of an increased risk of complications. In that case, surgical resection should be recommended before pregnancy. HCA in pregnant women implies special considerations, therefore, additional data from different centres for the risk of hormone induced growth and rupture of the adenoma during pregnancy are needed.
Conflict of Interests
The authors who have taken part in this study declare that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.
